Business & regional news

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies

Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency

SCAI 2023 Scientific Sessions: Harmony™ Transcatheter Pulmonary Valve System Demonstrates Strong Clinical and Hemodynamic Outcomes at Two Years

Presented at Charing Cross, 10-Year Clinical Data from Global ENGAGE OUS Registry Support Endurant Stent Graft System’s AAA Market-Leading Position Worldwide

ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years